Clinical TrialMay 5, 2026, 07:51 AM
Climb Bio Reports Positive Budoprutug SC Data; ITP Data Due June
AI Summary
Climb Bio, Inc. announced positive topline data for its budoprutug subcutaneous formulation, demonstrating robust B-cell depletion and good tolerability in healthy volunteers. The company's clinical trials for budoprutug in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE) are enrolling as planned. Initial data from the ITP trial is expected in June 2026, with pMN and SLE data anticipated in Q4 2026. Budoprutug also received Fast Track Designation for pMN.
Key Highlights
- Positive topline data reported for budoprutug subcutaneous formulation in healthy volunteers.
- Robust B-cell depletion observed with budoprutug SC, similar to IV administration, and was well-tolerated.
- Initial data from the ITP Phase 1b/2a study is anticipated in June 2026.
- Initial data from pMN Phase 2 and SLE Phase 1b studies are anticipated in Q4 2026.
- Budoprutug received Fast Track Designation from the FDA for primary membranous nephropathy (pMN).
- Clinical trials for budoprutug in pMN, ITP, and SLE are enrolling to plan.
Price Impact
More from CLYM